The Launch of Eight Novel Disease-Modifying Therapies, Including the First Oral Agents Approved for the Indication, Will Drive Modest Growth in the Multiple Sclerosis Drug Market Through 2019
Advertisement
Novartis/Mitsubishi Tanabe Pharma's FTY-720 and Merck Serono/EMD Serono's Oral Cladribine Will Have the Most Significant Market Impact, According to Findings from Decision Resources